Agoracom Blog Home

Author Archive

Draganfly $DFLY.ca $DFLYF Selected to Provide Engineering and Development Services for Drone Based Air Support Defense System $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 9:26 AM on Thursday, January 21st, 2021
  • Selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc.
  • Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.
  • Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms.

Los Angeles, CA, Jan. 21, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, today announced it has been selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions Inc. (“ILS”)

Integrated Launcher Solutions Inc. is a systems development and technical integration services company headquartered in Ontario with operations in Florida, with a vision to continually improve launch, range and space systems for its client base of US defense organizations and contractors.

Draganfly will provide Integrated Launcher Solutions Inc. development and engineering expertise and services for the deployment of a non-lethal 40mm multi-launching system that can be mounted and deployed on drones, robots and other remote or autonomous platforms. The main use case of the launch system is public disturbance management for military and public safety organizations.

“ILS approached Draganfly for this project because we are extremely impressed with their innovation in engineering,” said Greg Sullivan, CEO, Integrated Launcher Solutions. “Our client base requires North American developed and made solutions. Draganfly has the expertise to get this project executed.”

“We are honored at the confidence that Integrated Launcher Solutions has placed with Draganfly in overseeing the development of this very important drone technology,” said Cameron Chell, CEO Draganfly. “I am confident that the Draganfly team will provide the right set of expertise and management to develop the non-lethal ILS Air support Defense System.”

Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/753565-draganfly-selected-to-provide-engineering-and-development-services-for-drone-based-air-support-defense-system/messages/2299226#message

$HPQ.ca Gen1 Nano Silicon Reactor Exceeds Expectations, Produces Sub 100 Nm Spherical #Nanopowders & #Nanowires $ENPH $BE $NNO.ca $PYR.ca

Posted by AGORACOM-JC at 8:18 AM on Thursday, January 21st, 2021

Low-Cost Manufacturing of Nano Silicon Materials

  • Gen1 NSiR system performance exceeded design and modelling expectations:
    • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires.
    • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.

MONTREAL, Jan. 21, 2021 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ), through its wholly – owned subsidiary, HPQ Nano Silicon Powders inc (“HPQ NANO”), is pleased to update shareholders on milestones achieved during ongoing Gen1 PUREVAP TM Nano Silicon Reactor (“NSiR”) commissioning tests conducted by technology provider PyroGenesis Canada Inc. ( TSX: PYR ) .

“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications, as we continue working on scaling up the capabilities of our PUREVAP TM NSiR process.” said Bernard Tourillon, President and CEO HPQ Silicon.

PUREVAP TM NSiR LOW-COST PROCESS: FIRST RESULTS ENCOURAGING, MORE TESTING TO FOLLOW

The material produced, under the less than optimum operating conditions of the first commissioning tests, was analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD) and yielded the following information:

  • Gen1 NSiR system performance exceeded design and modelling expectations:
    • Successfully produced sub 100 nm silicon – based spherical nanopowders & nanowires.
    • Computer models suggested that the size limit of the material produced would be between 100 nm and 200 nm.
  • SEM-XRD analysis indicates that the < 100 nm Si base spherical nanopowders & nanowires material could be used as anode material for Li-ion batteries, combined with graphite or not.
  • Samples from these commissioning tests have been sent to Professor Lionel ROUÉ of the Centre Énergie Matériaux Télécommunications (EMT) for electro-chemical evaluation.
  • Using results from data collected during these preliminary tests, PyroGenesis technical team has improved the design of the system and the operational parameters of the reactor.
    • It will be possible to provide further inputs and controls on the process to customize the composition and size of the spherical nano powders and nano wires.
  • The Gen1 NSiR is now ready to commence further testing of Silicon nano materials under new conditions, with a goal of producing larger size Silicon (Si) nanopowders and nanowires.

A METHODICAL APPROACH TO THE COMMERCIAL DEVELOPMENT OF OUR DISRUPTIVE TECHNOLOGY

Despite massive investment in Silicon material for batteries , current manufacturing processes are simply not scalable or commercially viable. The PUREVAP TM NSiR represents a game changing leap forward in resolving the issues of commercial viability and scalability, and with the Gen1 NSiR now operational, HPQ NANO is uniquely well positioned to offer industry participants a wide spectrum of products for testing.

The scale of the Gen1 PUREVAP TM NSiR allows HPQ NANO technical provider PyroGenesis to take full advantage of a quick R&D feedback loop during the testing phase. Over short periods, tests are completed, material produced is analysed by scanning electron microscope (SEM) imaging combined with X-ray diffraction (XRD), operational parameters are reviewed and system modifications and/or operational improvements are implemented. This is the key to our methodical approach of developing a truly disruptive low-cost technology that is going to change nano silicon materials manufacturing.

Tourillon added HPQ’s Silicon R&D consortium has the depth and flexibility to meet the challenges as we strive to produce products for renewable energy storage participants and electric vehicle manufacturers, who are searching for cost effective ways of increasing the Silicon contained in their batteries . Silicon’s potential to meet energy storage demand is undeniable, generating massive investments , and serious industry interest. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”

Read More: https://agoracom.com/ir/HPQ-SiliconResources/forums/discussion/topics/753558-hpq-gen1-nano-silicon-reactor-exceeds-expectations-produces-sub-100-nm-spherical-nanopowders-nanowires/messages/2299217#message

Avicanna $AVCN.ca $AVCNF Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:07 AM on Thursday, January 21st, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.
  • Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

TORONTO, Jan. 21, 2021– Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia. Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

Initiation of pre-clinical studies on RHO Phyto in collaboration with University of Guelph

Further to Avicanna’s previous announcement regarding Dr. Khokhar’s research team at the University of Guelph being awarded a Natural Sciences and Engineering Research Council of Canada (“ NSERC ”) Alliance grant focused on the neurobiological underpinnings of cannabis toxicosis with the aim to evaluate Avicanna’s formulations in the treatment of cannabis-induced toxicosis, the project is now being expanded. The expansion of the project includes pharmacokinetic and behavioural testing of Avicanna’s RHO Phyto™ formulations as well as studying their efficacy in alleviating neuropathic pain and addiction. The data generated from the research will help guide Avicanna’s clinical development, including the pharmaceutical and real-world evidence studies related to the RHO Phyto formulations, and will provide additional information to health care practitioners who are recommending and prescribing the products in several markets.

COVID-19 drug candidate project update

The research collaboration with the University of Toronto on the development of a drug candidate to treat lung inflammation caused by COVID-19, with funding support from an NSERC Alliance grant and a MITACS Alliance grant, is complete. The peer-reviewed grants were focused on the development of a cannabinoid formulation to be used for further research on COVID-19. The physical and chemical characterization of the optimized cannabinoid formulation is complete, which included its stability and drug release properties in relevant conditions.

COVID-19 and anti-inflammatory related research collaboration with TRU with non-dilutive funding

In partnership with Avicanna, Dr. Kingsley Donkor and collaborators from Thompson Rivers University (” TRU ”), will be evaluating naturally derived cannabinoids and candidate formulations for their efficacy to modulate the receiving receptor of COVID-19 (angiotensin-converting ACE2 gene expression). This project will focus on elucidating the mechanism of action of novel prophylactic nasal and oral cannabinoid products for humans that target ACE2 viral gateways. Candidate formulations, once identified, will be evaluated for anti-inflammatory effects in human-derived lung tissue models. The research with TRU is supported by an NSERC grant and a MITACS Internship.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/753556-avicanna-initiates-pre-clinical-and-behavioural-studies-on-its-rho-phyto-formulary-with-university-of-guelph-and-provides-research-and-management/messages/2299215#message

Empower Clinics $CBDT.ca $EPWCF Doubling KAI Medical Laboratory Size In Anticipation Of Test Volumes By End Of Q1. Files MDEL Application With Health Canada To Import and Sell KAI Saliva PCR Test In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:58 AM on Thursday, January 21st, 2021

  • Announced significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.
  • In addition, Empower has filed a Medical Device Establishment Licence with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test, which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

VANCOUVER, BC / January 21, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased to announce significant expansion of our KAI Medical Laboratory in Dallas, Texas in anticipation of projected growth in COVID-19 testing requirements in the U.S., Canada and international markets.

In addition, Empower has filed a Medical Device Establishment Licence (“MDEL”) with Health Canada for the purposes of importing, distributing and selling our KAI Medical COVID-19 Saliva Test (“KAI Saliva”), which has experienced immediate success since it’s launch on December 15, 2020 in the United States and reported on January 7, 2021.

KAI MEDICAL LABORATORY EXPANDING TO AT LEAST DOUBLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH IN VOLUME

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower, with Q4 COVID-19 test kit volumes exceeding 6,000 units, far surpassing the 1,300 total units prior to acquisition.

Current run rate projections now indicate as follows:

  • January 2021 is expected to exceed 8,000 tests, surpassing all of Q4 2020
  • February 2021 could see daily rates hit 1,000 tests per day
  • March 2021 could see daily rates hit 2,000 tests per day

These run rates DO NOT include the recent 25,000 unit order for KAI Saliva test kits, nor do they include any test kits from the launch of KAItests.com

Empower Clinics CEO, Steven McAuley stated “Our investment in R&D is really starting to pay off for KAI Medical, starting with a new state-of-art laboratory information system to automate processes for the anticipated growth in volume. Next, we have hired three new scientists, increased administrative staff and are activating a call center to provide world-class customer support. Further, the investment in new test protocols such as the Kai Saliva test kit, combined with our Health Canada medical device licence, positions us to be a leader in the reactivation of travel for Canadians.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/753555-empower-clinics-doubling-kai-medical-laboratory-size-in-anticipation-of-test-volumes-by-end-of-q1-files-mdel-application-with-health-canada-to/messages/2299214#message

VIDEO – Mountain Valley MD $MVMD.ca Patent Filing Creates New Global Delivery And Patient Delivery Model That Can Eradicate Polio From The World …. Then Other Viruses $CTLT $MRNA $NVAX

Posted by AGORACOM-JC at 6:55 PM on Wednesday, January 20th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/01/Mountain-Valley-300x300-1.jpg

Let us start off by saying this interview may be the best one we’ve done in the last 10 years.  Here is why.

When Mountain Valley MD issued this press release today, you wouldn’t be alone if you declared “I really don’t know what that means”.  The fact of the matter is that MVMD is a double-edged sword that puts it in a position to quite potentially change the way the world delivers drugs and vaccines via physical transport and into the body of patients who need them most.  The flip-side of creating something so cutting edge is that it makes it very difficult to understand for anybody without a Life Sciences PhD.

Fortunately, this is where AGORACOM comes in to bridge the worlds between MVMD and the investment community.  To do that, the first thing you have to understand is the following:

MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better.  Both Into The Body and By Transportation To The World. Way Better.

For the purposes of introducing you to MVMD, we’ll use vaccines as an example given the state of the world since COVID-19 arrived.  Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years.  One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.

BUT 

One thing we don’t know or understand about vaccinations is that they are only as good as:

1.  The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;

2.  The delivery system into your body (i.e. injection)

If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good.

This is where MVMD comes in.  They don’t make vaccines, drugs or pharmaceuticals.

What they do is make their delivery better.  Their physical delivery until their ultimate delivery into your body – and that is very good.

By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.

CAN MVMD CREATE A WORLD WITHOUT POLIO … AND THEN OTHER VIRUSES? THEY JUST MIGHT

With the information above in mind, you can now start to get a sense of the power of this quote from MVMD CEO, Dennis Hancock:

“Using a fraction of the Inactivated Polio Vaccine, applying advanced Quicksome™ thin film inside a vial that can be distributed completely outside of the cold chain, and administering through needleless applications is the formula to help us achieve our vision of a world without Polio“. 

If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.

VIDEO – POET Technologies $PTK.ca $POETF Discusses Opening of Product Design and Development Center in Shenzhen, China

Posted by AGORACOM-JC at 9:09 AM on Wednesday, January 20th, 2021

Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Immersive Tech, Announces the Creation of World’s First #COVID-safe Location-Based Entertainment (LBE) Virtual Reality #VR Division “UNCONTAINED” $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 8:42 AM on Wednesday, January 20th, 2021
Victory Square Technologies | LinkedIn
  • Company launches first-ever COVID-safe location-based (LBE) Virtual Reality attractions division “UNCONTAINED” to disrupt the marketplace and fulfill demand from its Family Entertainment Center (FEC) clients.
  • Immersive Tech is planning for a public listing in the first half of 2021.
  • Leading immersive experience company builds upon current and past relationships with major companies.
  • Announcement brings creation of the world’s first-ever free-roam interactive VR franchise attraction available for rapid sale to the global attraction and entertainment marketplace.

VANCOUVER, British Columbia, Jan. 20, 2021 — Victory Square Technologies Inc. (“VST”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) , a company that provides investors access to a diverse portfolio of companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, is pleased to announce that its portfolio company Immersive Tech (“Company”) has launched a premiere new Location-Based Entertainment (LBE) VR attractions division named UNCONTAINED to capitalize on the growing demand for COVID-safe attractions. UNCONTAINED will be the world’s first free-roam interactive VR franchise attraction, built for a COVID world within shipping containers. The experience will allow for up to six players to roam freely within the container while interacting inside a digital environment as a team while making decisions that help guide and define the story.

Immersive Tech designs, engineers and builds custom technology-driven experiences, whether they facilitate brand integration or are aiming to create the best real life adventure possible. The Company recently announced the creation of three unique entertainment escape rooms custom designed and built for Apex Entertainment’s new location in Virginia Beach VA, USA. The three custom room themes include an underwater submarine adventure, a post-war bunker experience, and an AI-controlled warship gone rogue featuring a race against time and a family-friendly focus.

“UNCONTAINED” leverages the manner of design experience that Immersive Tech has gained and honed over the past four years in creating and launching highly successful interactive escape rooms for Family Entertainment Centers. This is complemented by a fundamental understanding of shipping containers as highlighted in their recent 3-room escape experience for Leaps by Bayer, a Bayer Pharmaceutical company, in 2020.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/753450-victory-square-technologies-portfolio-company-immersive-tech-announces-the-creation-of-world-s-first-covid-safe-location-based-entertainment/messages/2299018#message

Datametrex $DM.ca $DTMXF Expands LOTTE Agreements $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:59 AM on Wednesday, January 20th, 2021
  • Announced that it has renewed and extended its current sales agreements on January 15, 2021, with LOTTE Global Logis, LOTTE Duty-Free Shops, and LOTTE Home Shopping, LOTTE Super, collectively LOTTE for technology services and maintenance.
  • The aggregate gross revenue from these agreements is approximately $500,000 CAD with the gross margin of $259,000.

Toronto, Ontario–(January 20, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”), is pleased to announce that it has renewed and extended its current sales agreements on January 15, 2021, with LOTTE Global Logis, LOTTE Duty-Free Shops, and LOTTE Home Shopping, LOTTE Super, collectively LOTTE (“LOTTE”) for technology services and maintenance. The aggregate gross revenue from these agreements is approximately $500,000 CAD with the gross margin of $259,000.

Datametrex is a continued preferred vendor partner for LOTTE, and vendors on this platform have demonstrated quality, reliability, and trustworthiness.

“These extended agreements with LOTTE further confirm Datametrex’s business strategy for generating revenue from its diverse portfolio of AI technology and cybersecurity products,” commented Marshall Gunter, CEO of Datametrex.

Source: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/753446-datametrex-expands-lotte-agreements/messages/2299012#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Advances BioCloud Technology for European Sales and Provides Update $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:48 AM on Wednesday, January 20th, 2021
kontrol-logo
  • Announced that it continues to advance the deployment of its BioCloud technology
  • Initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications
  • In the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications
  • “We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

TORONTO, ON / January 20, 2021 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it continues to advance the deployment of its BioCloud technology.

“We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

Non-Disclosure Agreement (NDA)

BioCloud has entered into a Non-Disclosure Agreement, with a leading medical sports authority, to share the full scope of BioCloud’s patents and research. The purpose of the NDA is to advance various potential sport applications. Such applications include, but are not limited to, dressing rooms and training facilities.

BioCloud European Standards

Kontrol has initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications, which is an important prerequisite for European sales. As part of the product requirements for each country within the European Union there may be further standards approval required but these will be dealt with on a case-by-case basis.

Distribution Network

Kontrol has recently added a South Korean firm to its growing distribution network and is in discussion with numerous interested parties.

Viral/Pathogen Advisory Committee

Kontrol is in the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications. Kontrol seeks to establish the committee in February 2021.

Corporate Name Change

Kontrol’s corporate name change to Kontrol Technologies Corp. is anticipated to be completed by the end of January 2021. There has been no specific delay in the process other than the time it takes to complete filings between B.C. and Ontario corporate registries and all of the associated requirements.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/753445-kontrol-advances-biocloud-technology-for-european-sales-and-provides-update/messages/2299011#message

VIDEO – Valeo Pharma $VPH.ca $VPHIF Starts Off 2021 With A Bang As MDBriefcase Validates Key Ingredients In Its Immune System Support Product $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma (@valeo_pharma) | Twitter

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • $5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
  • 9 products currently in the market with an annual estimated peak sales of $40M/year
  • 7 products in the pipeline with an annual estimated peak sales of $45M/year

In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:

  • $6.9M Bought Deal financing at $1.20/shares
  • A $1.7M Oversubscribed debenture (non-convertible) 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight. 

Saviuk agreed and gave the following reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

Well there you have it.  Valeo is a great story. Watch the video.

HOLD ON. THERE’S MORE … A LOT MORE

In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease.  What does this mean?

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
  • Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.

Now you have it.  That’s the Valeo story as it applies to just 2 of their amazing products.  There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.